Home > Insider Trading > Filing (0001213900-22-074313)

Filing Details

Accession Number:: 0001213900-22-074313
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-11-21 18:26:10
Reporting Period:: 2022-11-17

Accepted Time:: 2022-11-21 18:26:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1781174	Acrivon Therapeutics Inc.	ACRV	()	G4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1590232	Ltd Chione	Simou Menardou 5, Kifisia Court, Office 225 Larnaca G4 6015	No	No	Yes	No
1591256	Andreas Hadjimichael	C/O Chione Limited Simou Menardou 5, Kifisia Court, Office 225 Larnaca G4 6015	No	No	Yes	No
1591274	Wiaczeslaw Smolokowski	Chalet Lenotchka Ch.de Barnoud 1885 Chesieres Switzerland V8 1885	No	No	Yes	No
1591275	Marcin Czernik	C/O Chione Limited Simou Menardou 5, Kifisia Court, Office 225 Larnaca G4 6015	No	No	Yes	No
1954186	Anastasis Nikolaou	C/O Chione Limited Simou Menardou 5, Kifisia Court, Office 225 Larnaca G4 6015	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-11-17	400,000	$12.50	3,856,597	No	4	P	Direct
Common Stock	Acquisiton	2022-11-17	3,445,940	$0.00	3,856,597	No	4	C	Direct
Common Stock	Acquisiton	2022-11-17	10,657	$0.00	3,856,597	No	4	C	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	C	Direct
No	4	C	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2022-11-17	8,497,692	$0.00	3,445,940	$0.00
Common Stock	Series B Preferred Stock	Disposition	2022-11-17	26,281	$0.00	10,657	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date.
Shares owned directly by Chione Limited ("Chione").
Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione.
Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.